Securities code: Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) securities abbreviation: Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) Announcement No.: 2022012 Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864)
Announcement on the issuance results of public issuance of convertible corporate bonds
Sponsor (lead underwriter): Zhongtai Securities Co.Ltd(600918)
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) (hereinafter referred to as the “issuer”) has obtained the approval of the China Securities Regulatory Commission (CSRC) zjxk [2021] No. 3323 for the public issuance of convertible corporate bonds (hereinafter referred to as “convertible bonds” or “Panlong convertible bonds”). The sponsor (lead underwriter) of this offering is Zhongtai Securities Co.Ltd(600918) (hereinafter referred to as “sponsor (lead underwriter)” or ” Zhongtai Securities Co.Ltd(600918) “. The convertible bonds issued this time are referred to as “Panlong convertible bonds” for short, and the bond code is “127057”.
The scale of the convertible bonds issued this time is RMB 276 million, and the face value of each is RMB 100, that is, the number of convertible bonds that investors can apply for is 2760000, which are issued at face value. The convertible bonds issued this time shall be placed preferentially to the original shareholders registered by China Securities Depository and Clearing Co., Ltd. Shenzhen Branch (hereinafter referred to as “CSDCC Shenzhen Branch”) after the closing of the market on the equity registration date (March 2, 2022, t-1), The balance after the preferential placement of the original shareholders (including the part that the original shareholders give up the preferential placement) is issued to the public investors online through the trading system of Shenzhen Stock Exchange (hereinafter referred to as “Shenzhen Stock Exchange”).
1、 The result of the preferential placement of convertible bonds by the original shareholders
The payment for the preferential placement of the original shareholders in this issuance has been completed on March 3, 2022 (t day). 2216811 Panlong convertible bonds have been allocated to the original shareholders in this issuance, with a total of 22168110000 yuan, accounting for 80.32% of the total amount of this issuance.
2、 Online subscription results of convertible bonds
The online subscription and payment of the balance after the preferential placement of the original shareholders (including the preferential placement abandoned by the original shareholders) has been completed on March 7, 2022 (T + 2).
The sponsor (lead underwriter) made statistics on the final subscription of this online offering according to the data provided by Shenzhen Stock Exchange and China Clearing Shenzhen Branch. The results are as follows:
1. Number of convertible bonds subscribed by online investors (pieces): 536279
2. Subscription amount paid by online investors (yuan): 5362790000
3. Number of convertible bonds that online investors give up subscription (piece): 6901
4. Amount of subscription abandoned by online investors (yuan): 69010000
3、 Underwriting by the recommendation institution (lead underwriter)
According to the underwriting agreement, the amount of convertible bonds that the online investors give up the subscription shall be underwritten by the sponsor (lead underwriter). In addition, the announcement on the issuance of Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) public issuance of convertible corporate bonds stipulates that every 10 online subscriptions are one subscription unit, and every one is one subscription unit for priority placement to the original shareholders. Therefore, the issuance balance of 9 sheets is underwritten by the sponsor (lead underwriter). The total number of convertible bonds underwritten by the recommendation institution (lead underwriter) is 6910, the underwriting amount is 69100000 yuan, and the underwriting proportion is 0.25%.
On March 9, 2022 (T + 4), the recommendation institution (lead underwriter) transferred the subscription funds of convertible bonds to the issuer after deducting the recommendation and underwriting fees according to the underwriting agreement. The issuer submitted a registration application to CSDCC Shenzhen Branch and registered the underwritten convertible bonds to the Zhongtai Securities Co.Ltd(600918) designated securities account.
4、 Contact information of sponsor (lead underwriter)
If investors have any questions about the issuance results announced in this announcement, please contact the sponsor (lead underwriter) of this issuance. The specific contact information is as follows:
Sponsor (lead underwriter): Zhongtai Securities Co.Ltd(600918)
Contact: capital market department
Tel: 01059013948, 01059013949
Issuer: Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) sponsor (lead underwriter): Zhongtai Securities Co.Ltd(600918) March 9, 2022 (this page has no text and is the seal page of the announcement on the issuance results of Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) public issuance of convertible corporate bonds)
Issuer: Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) March 9, 2022 (there is no text on this page, which is the seal page of the announcement on the issuance results of Shanxi Panlong Pharmaceutical Group Limited By Share Ltd(002864) public issuance of convertible corporate bonds)
Sponsor (lead underwriter): Zhongtai Securities Co.Ltd(600918) March 9, 2022
